Actively Recruiting
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
Led by Peking University First Hospital · Updated on 2026-04-24
140
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Visceral pain following laparoscopic surgery is frequently underestimated, yet it is associated with a range of adverse outcomes. Effective visceral pain management should constitute an essential component of postoperative analgesic strategies following laparoscopic procedures. However, conventional analgesic agents, including μ-opioid receptor agonists, lack specificity for visceral pain. Anrikefon, a novel selective peripheral κ-opioid receptor agonist, demonstrates unique efficacy in alleviating visceral pain with a favorable safety profile. Preliminary studies showed that a single intravenous dose of anrikefon effectively alleviates postoperative pain after abdominal surgery with a low risk of adverse effects. The investigators hypothesize that an appropriate dosing regimen of anrikefon administered via patient-controlled intravenous analgesia (PCIA) pump, as part of a multimodal analgesic strategy, can specifically target and alleviate visceral pain after laparoscopic surgery, thereby achieving comprehensive postoperative analgesia.
CONDITIONS
Official Title
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older but younger than 75 years
- Scheduled for elective laparoscopic colorectal surgery lasting 1 hour or more
- Incisional pain covered by transversus abdominis plane block or rectus sheath block but still needing postoperative patient-controlled intravenous analgesia
You will not qualify if you...
- Preoperative cognitive impairment (Mini-Mental State Examination score below 27) or inability to communicate due to language barriers
- Body mass index over 30 kg/m² or under 18 kg/m²
- Poorly controlled or untreated comorbidities such as severe hypertension, recent unstable angina or heart attack, severe heart failure, severe lung disease, severe liver or kidney failure, or very high anesthesia risk
- Continuous opioid use for more than 10 days or alcohol abuse within 3 months before screening
- Recent use of opioid or non-opioid analgesics without sufficient time before randomization
- Known allergies or contraindications to opioids, anesthetics, antiemetics, or NSAIDs
- Expected need for postoperative mechanical ventilation
- Other conditions deemed unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
D
Dong-Xin Wang, MD, PhD
CONTACT
C
Chun-Qing Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here